Allosteric Effectors of Hemoglobin: Past, Present and Future

Chemistry and Biochemistry of Oxygen Therapeutics: From Transfusion to Artificial Blood

Volumn , Issue , 2011, Pages 285-300

  Safo, Martin K ^a   Bruno, Stefano ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Allosteric effectors of hemoglobin past, present and future; Allosteric equilibrium of Hb modulated by effectors; Chemistry, mechanism of naturally occurring small molecules altering Hb allosteric properties; Fully oxygenated RBCs oxygen in larger vessels lesser at arterioles, most at capillaries; Hb allosteric effector studies understanding concept of intrinsic activity; Hemoglobin (Hb), most studied and understood example of allosteric protein; Hemoglobin allosteric effectors clinical importance; Molecular mechanism of allosteric effector action oxygen binding curve; Natural and synthetic allosteric effectors organic phosphates, affecting oxygen affinity of Hb; Regulatory vasoconstriction arterioles, leading to cell sickling

Indexed keywords

EID: 84885807721     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119975427.ch21     Document Type: Chapter

References (61)

1. Perutz, M. F. Stereochemistry of cooperative effects in hemoglobin, Nature, 228, 726-734 (1970).
2. Baldwin, J.and Chothia, C.Haemoglobin, the structural changes related to ligand binding and its allosteric mechanism, J.Mol.Biol., 129, 175-220 (1979).
3. Monod, J., Wyman, J., Changeux J.P.On the nature of allosteric transitions: a plausible model, J.Mol.Biol., 12, 88-118 (1965).
4. Koshland, D.E.Jr, Némethy, G., Filmer, D.Comparison of experimental binding data and theoretical 30 models in proteins containing subunits, Biochemistry, 5, 365-385 (1966).
5. Perutz, M.F.Nature of haem-haem interaction, Nature, 237, 459-499 (1972).
6. Perutz, M.F.Mechanisms of cooperativity and allosteric regulation in proteins, Q.Rev.Biophys., 22, 139-237 (1989).
7. Perutz, M.F., Wilkinson A.J., Paoli, M., Dodson, G.G.The stereochemical mechanism of the cooperative effects in hemoglobin revisited, Annu.Rev.Biophys.Biomol.Struct ., 27, 1-34 (1998).
8. Lukin, J.A., Kontaxis, G., Simplaceanu, V.et al.Quaternary structure of hemoglobin in solution, Proc.Natl.Acad.Sci.U S A, 100, 517-520 (2003).
9. Sawicki C.A., Gibson, Q.H.Quaternary conformational changes in human hemoglobin studied by laser photolysis of carboxyhemoglobin, J.Biol.Chem., 251, 1533-1542 (1976).
10. Jayaraman, V., Spiro, T.G.Structure of a third cooperativity state of hemoglobin, ultraviolet resonance Raman Spectroscopy of cyanomethemoglobin ligation microstates, Biochemistry, 34, 4511-4515 (1995).
11. Perrella, M., Di Cera, E.CO ligation intermediates and the mechanism of hemoglobin cooperativity, J.Biol.Chem., 274, 2605-2608 (1999).
12. Silva, M.M., Rogers, P.H., Arnone, A.A third quaternary structure of human hemoglobin A at 1.7-°A resolution, J.Biol.Chem., 267, 17248-17256 (1992).
13. Mueser, T.M., Rogers, P.H., Arnone, A.Interface sliding as illustrated by the multiple quaternary structures of liganded hemoglobin, Biochemistry, 39, 15353-15364 (2000).
14. Safo, M.K., Abraham, D.J.The enigma of the liganded hemoglobin end-state, a novel quaternary structure of human carbonmonoxy hemoglobin, Biochemistry, 44, 8347-8359 (2005).
15. Safo, M.K., Abdulmalik, O., Danso-Danquah, R.et al.Structural basis for the potent antisickling effect of a novel class of 5-membered heterocyclic aldehydic compounds, J.Med.Chem., 47, 4665-4676 (2004).
16. Jenkins, J.D., Musayev, F.N., Danso-Danquah, R., et al.Structure of relaxedstate human hemoglobin, insight into ligand uptake, transport and release, Acta Crystallogr.D, 65, 41-48 (2009).
17. Benesch, R., Benesch, R.E.The effect of organic phosphates from the human erythrocyte on the allosteric properties of hemoglobin, Biochem.Biophys.Res.Commun., 26, 162-167 (1967).
18. Arnone, A.X-ray diffraction study of binding of 2,3-diphosphoglycerate to human deoxyhaemoglobin, Nature, 237, 146-149 (1972).
19. Schay, G., Smeller, L., Tsuneshige, A., et al.Allosteric effectors influence the tetramer stability of both R- and T-states of hemoglobin A, J.Biol.Chem., 281, 25972-25983 (2006).
20. Tsuneshige, A., Kanaori, K., Samuni, U., et al.Semihemoglobins, high oxygen affinity dimeric forms of human hemoglobin respond efficiently to allosteric effectors without forming tetramers, J.Biol.Chem., 279, 48959-48967 (2004).
21. Yonetani, T., Tsuneshige, A.The global allostery model of hemoglobin, an allosteric mechanism involving homotropic and heterotropic interactions, C.R.Biologies, 326, 523-532 (2003).
22. Gong, Q., Simplaceanu, V., Lukin, J.A., et al.Quaternary structure of carbonmonoxyhemoglobins in solution, structural changes induced by the allosteric effector inositol hexaphosphate, Biochemistry, 45, 5140-5148 (2006).
23. Teisseire, B., Ropars, C., Villereal, M.C., Nicolau, C.Long-term physiological effects of enhanced O2 release by inositol hexaphosphate-loaded erythrocytes, Proc.Natl.Acad.Sci.U S A, 84, 6894-6898 (1987).
24. Cabrales, P., Tsai, A.G., Intaglietta, M.Modulation of perfusion and oxygenation by red blood cell oxygen affinity during acute anemia, Am.J.Resp.Cell Mol., 38, 354-361 (2008).
25. Bourgeaux, V., Hequet, O., Campion, Y., et al.Inositol hexaphosphate-loaded red blood cells prevent in vitro sickling, Transfusion, 50, 2176-2184 (2010).
26. Fylaktakidou, K.C., Lehn, J.M., Greferath, R., Nicolau, C.Inositol tripyrophosphate, a new membrane permeant allosteric effector of haemoglobin, Bioorg.Med.Chem.Lett ., 15, 1605-1608 (2005).
27. Kieda, C., Greferath, R., Crola da Silva, C., et al.Suppression of hypoxiainduced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes, Proc.Natl.Acad.Sci.U S A, 103, 15576-15581 (2006).
28. Biolo, A., Greferath, R., Siwik, D.A., et al.Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate, Proc.Natl.Acad.Sci.U S A, 106, 1926-1929 (2009).
29. Abraham, D.J., Perutz, M.F., Phillips, S.E.Physiological and x-ray studies of potential antisickling agents, Proc.Natl.Acad.Sci.U S A, 80, 324-328 (1983).
30. Perutz, M.F., Poyart, C.Bezafibrate lowers oxygen affinity of haemoglobin, Lancet, ii, 881-882 (1983).
31. Perutz, M.F., Fermi, G.Hemoglobin as a receptor of drugs and peptides, X-ray studies of the stereochemistry of binding, J.Am.Chem.Soc., 108, 1064-1078 (1986).
32. Lalezari, I., Lalezari, P., Poyart, C., et al.New effectors of human hemoglobin, structure and function, Biochemistry, 29, 1515-1523 (1990).
33. Yokoyama, T., Neya, S., Tsuneshige, A., et al.R state haemoglobin with low oxygen affinity, crystal structures of deoxy human and carbonmonoxy horse haemoglobin bound to the effector molecule L35, J.Mol.Biol., 356, 790-801 (2006).
34. Chen, Q., Lalezari, I., Nagel, R.L., Hirsch, R.E.Liganded hemoglobin structural perturbations by the allosteric effector L35, Biophys.J ., 88, 2057-2067 (2005).
35. Shibayama, N., Miura, S., Tame, J.R., et al.Crystal structure of horse carbonmonoxyhemoglobin-bezafibrate complex at 1.55-°A resolution: a novel allosteric binding site in R state hemoglobin, J.Biol.Chem., 277, 38791-38796 (2002).
36. Ascenzi, P., Coletta, M., Desideri, A., et al.Effect of bezafibrate and clofibric acid on the spectroscopic properties of the nitric oxide derivative of ferrous human hemoglobin, J.Inorg.Biochem., 48, 47-53 (1992).
37. Safo, M.K., Moure, C.M., Burnett, J.C., et al.High resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector, Protein Sci ., 10, 951-957 (2001).
38. Grinberg, O.Y., Miyake, M., Hou, H., et al.The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats, Adv.Exp.Med.Biol., 530, 287-296 (2003).
39. Khandelwal, S.R., Randad, R.S., Lin, P.S., et al.Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation, Am.J.Physiol., 265, H1450-H1453 (1993).
40. Kunert, M.P., Liard, J.F., Abraham, D.J.RSR13, an allosteric effector of hemoglobin, increases systemic and iliac vascular resistance in rats, Am.J.Physiol ., 271, H602-H613 (1996).
41. Suh, J.H., Stea, B., Nabid, A., et al.Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases, J.Clin.Onc., 24, 106-114 (2006).
42. Stea, B., Suh, J.H., Boyd, A.P., et al.Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases, determinants of response and its prognostic value for subsequent survival, Int.J.Radiat.Oncol.Biol.Phys., 64, 1023-1030 (2006).
43. Kaal, E.C., Vecht, C.J.CNS complications of breast cancer, current and emerging treatment options, CNS drugs, 21, 559-579 (2007).
44. Peacock, K.H., Lesser, G.J.Current therapeutic approaches in patients with brain metastases, Curr.Treat.Options Oncol., 7, 479-489 (2006).
45. Scott, C., Suh, J., Stea, B., et al.Improved survival, quality of life, and qualityadjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases, Am.J.Clin.Oncol., 30, 580-587 (2007).
46. Viani, G.A., Borges, G.M., Fonseca, E.C., et al.Whole brain radiotherapy with radiosensitizer for brain metastases, a meta-analysis of randomized controlled trials, Exp.Clin.Canc.Res., 28, 1 (2009).
47. Watanabe, T., Takeda, T., Omiya, S., et al.Reduction in hemoglobin-oxygen affinity results in the improvement of exercise capacity in mice with chronic heart failure, J.Am.Coll.Cardiol ., 52, 779-786 (2008).
48. Safo, M.K., Boyiri, T., Burnett, J.C., et al.X-ray crystallographic analyses of symmetrical allosteric effectors of hemoglobin, compounds designed to link primary and secondary binding sites, Acta Crystallogr., 58, 634-644 (2002).
49. Abraham, D.J., Wireko, F.C., Randad, R.S., et al.Allosteric modifiers of hemoglobin, 2-[4-[[3,5-dimethylanilino[(carbonyl)methyl]-phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats, Biochemistry, 31, 9141-9149 (1992).
50. Youssef, A.M., Safo, M.K., Danso-Danquah, R., et al.Synthesis and X-ray studies of chiral allosteric modifiers of hemoglobin, J.Med.Chem., 45, 1184-1195 (2002).
51. Phelps Grella, M., Danso-Danquah, R., Safo M.K., et al.Synthesis and structure-activity relationships of chiral allosteric modifiers of hemoglobin, J.Med.Chem., 43, 4726-4737 (2000).
52. Abraham D.J., Mehanna, A.S., Wireko, F.C., et al.Vanillin a potential agent for the treatment of sickle cell anemia, Blood, 77, 1334-1341 (1991).
53. Wireko, F.C., Abraham, D.J.X-ray diffraction study of the binding of the antisickling agent 12C79 to human hemoglobin, Proc.Natl.Acad.Sci.U S A, 88, 2209-2211 (1991).
54. Abdulmalik O., Safo, M.K., Chen, Q., et al.5-Hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells, Br.J.Haematol., 128, 552-561 (2005).
55. Nnamani, I.N., Joshi, G.S., Danso-Danquah, R., et al.Pyridyl derivatives of benzaldehyde as potential antisickling agents, Chem.Biodivers., 5, 1762-1769 (2008).
56. Beddell, C.R., Goodford, P.J., Kneen, G., et al.Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickled erythrocytes, Br.J.Pharmacol., 82, 397-407 (1984).
57. Zaugg, R.H., Walder, J.A., Klotz, I.M.Schiff-base adducts of hemoglobin: modifications that inhibit erythrocyte sickling, J.Biol.Chem., 252, 8542-8548 (1977).
58. Abraham, D.J., Safo, M.K., Boyiri, T., et al.How allosteric effectors can bind to the same protein residue and produce opposite shifts in the allosteric equilibrium, Biochemistry, 34, 15006-15020 (1995).
59. Boyiri, T., Safo, M.K., Danso-Danquah, R.E., et al.Bisaldehyde allosteric effectors as molecular ratchets and probes, Biochemistry, 34, 15021-15036 (1995).
60. Rosenberg, A., Knox, S.Radiation sensitization with redox modulators, a promising approach, Int.J.Radiat.Oncol.Biol.Phys., 64, 343-354 (2006).
61. Mehta, M.P., Khuntia, D.Current strategies in whole-brain radiation therapy for brain metastases, Neurosurgery, 57, S33-S44 disc.S1-S4 (2005).